Abstract

The primary goal of this study was to assess the efficacy of intensive aflibercept therapy in people with diabetic macular oedema (DME). The study additionally aimed to look into the modifiable systemic and ocular variables that affect therapy response in a practical scenario. Methodology: We conducted a retrospective analysis of the medical records of a cohort of patients diagnosed with diabetic macular oedema (DME). The evaluation of diabetic macular oedema (DME) involved the utilisation of central retinal thickness (CRT) and best-corrected visual acuity (BCVA). The study assessed the changes in contrast sensitivity and best-corrected visual acuity (BCVA) in response to each statistically significant factor. Results: The average central retinal thickness (CRT) and best-corrected visual acuity (BCVA) exhibited a significant improvement following the administration of five loading injections. Specifically, the CRT decreased to336.65 ± 61.223 from 486.97 ± 91.23 μm, while the BCVA improved to0.39 ± 0.21 LogMAR, with statistical significance (p < 0.05). Over the course of a 12-month follow-up period, it was seen that 16 eyes (53.33%) were able to sustain central retinal thickness (CRT) without requiring any supplementary treatment. Conclusion: In conclusion, administering five monthly loading doses of intravitreal aflibercept injection resulted in notable structural and optical enhancements among individuals diagnosed with diabetic macular oedema (DME).

Description